Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Durvalumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Durvalumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Durvalumab, an antibody targeting PD-L1.
Read →
Abexinostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Abexinostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Abexinostat: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Zilganersen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Zilganersen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Zilganersen: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Trastuzumab Pamirtecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Trastuzumab Pamirtecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Trastuzumab Pamirtecan: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Apitegromab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Apitegromab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Apitegromab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Ketosteril Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Ketosteril Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ketosteril: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Fluoride [18F] Thretide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Fluoride [18F] Thretide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Fluoride [18F] Thretide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Atezolizumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Atezolizumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atezolizumab, a antibody targeting PD-L1.
Read →
Benzyldodecyldimethylammonium bromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Benzyldodecyldimethylammonium bromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Benzyldodecyldimethylammonium bromide: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Gentuximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Gentuximab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Gentuximab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Avelumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Avelumab Biologics Sequence Review Report 2026: PD-L1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avelumab, a antibody targeting PD-L1.
Read →
Pimitespib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Pimitespib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Pimitespib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →